Full Press Release Details
Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023.
ZYME
Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023
Key Takeaway: Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023
Price reaction · baseline $8.8 (2023-05-24 close) · hit after-hours · clean, no other ZYME news in the window
day 0 close · peak
-4.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers